- Webinar
The Future of Small Molecules: Why Chemistry Is Far from Dead
Explore why small molecules remain relevant in modern drug discovery and how AI, chemistry, and emerging technologies are shaping their future in biopharma. This webinar highlights emerging opportunities and their strategic importance in pharmaceutical innovation.
Please fill this form to view webinar recording.
Register Now
- Your joining link will be sent to the email you register with.
Why this conversation matters now
The pharmaceutical innovation landscape is increasingly shaped by biologics, gene therapies, and cell therapies, often creating the perception that traditional small-molecule chemistry is losing its strategic relevance. However, small molecules continue to account for a substantial share of drug approvals and pharmaceutical revenues, supported by their established development pathways, manufacturing scalability, oral bioavailability, and cost advantages.
At the same time, advances in artificial intelligence, machine learning, computational chemistry, and structure-based drug design are transforming how small molecules are discovered, optimized, and developed. These technologies are enabling more precise molecular design, accelerating discovery pipelines, and creating new possibilities for addressing previously challenging biological targets.
What attendees will get
- Why small molecules remain relevant in an increasingly biologics-driven market.
- How cost advantages influence pharmaceutical affordability and accessibility.
- How AI and machine learning are transforming drug discovery.
- Which emerging technologies are accelerating molecular design.
- How development timelines influence investment and competitive strategies.
- Where future opportunities for small-molecule innovation may emerge.
Six themes, one decision window
-
1
Reassessing the Strategic Relevance of Small Molecules
Examining why small molecules remain a significant force in pharmaceutical innovation despite the growing attention surrounding biologics, gene therapies, and cell therapies. The discussion will explore their continued contribution to drug approvals, with small molecules accounting for nearly two-thirds of FDA approvals over the past decade.
-
2
The Economic Advantage of Small-Molecule Therapeutics
Exploring the cost and accessibility advantages that continue to make small molecules commercially relevant. With estimates indicating up to 22× lower cost per dose compared with biologics, the session will examine how affordability, manufacturing economics, and scalability influence pharmaceutical development and healthcare access.
-
3
Reinventing Drug Discovery Through Modern Chemistry
Assessing how traditional medicinal chemistry is evolving through computational approaches, machine learning, AI-driven molecular design, and advanced screening technologies. The discussion will also examine the projected growth of the drug discovery market to $103.1 billion by 2031 and the implications for future R&D investment.
-
4
AI-Driven Innovation and Accelerated Discovery Pipelines
Exploring how AI-enabled molecular design, predictive modelling, and data-driven discovery are transforming research productivity, with emerging approaches reporting up to 70% acceleration in certain small-molecule discovery pipelines. The session will consider how these capabilities can reduce development timelines and improve precision in identifying promising drug candidates.
-
5
Development Timelines and the Changing Investment Landscape
Evaluating how differences in development and approval timelines influence pharmaceutical investment strategies and competitive positioning. Small molecules may reach approval 0–2 years faster than biologics in certain comparisons, creating potential advantages in development efficiency, market entry, and portfolio planning.
-
6
Where Small-Molecule Innovation Creates Future Strategic Value
Examining the continued economic importance of small molecules, which are estimated to contribute approximately 70–85% of global pharmaceutical revenue. The discussion will explore how chemistry-led innovation can influence future R&D priorities, therapeutic development strategies, commercial competitiveness, and equitable healthcare access.
Our People
Tanu Kapoor
Tanu brings expertise in strategic consulting, innovation intelligence, and technology assessment, helping organizations navigate evolving scientific and competitive landscapes. Her work focuses on identifying emerging innovation opportunities, evaluating technology developments, and translating complex research and market signals into actionable strategic insights. Through structured intelligence and forward-looking analysis, she supports organizations in strengthening innovation strategies and making informed decisions across evolving industry ecosystems.
Damini Goyal
Damini brings experience in strategic consulting, innovation assessment, and translating emerging technology developments into commercially relevant opportunities. Her work focuses on evaluating innovation landscapes, understanding competitive dynamics, and identifying pathways that connect scientific advancements with market needs. By combining analytical rigor with a commercialization-oriented perspective, she helps organizations assess emerging opportunities, prioritize innovation initiatives, and navigate the evolving journey from concept to market.
Client Success Stories Highlighting How Our
Customized Consulting Solutions Contributed To Their Success & Growth
Defining Client Success: How Our Strategic Advisory Turns Complexity into Clarity”
Explore the Future of Small-Molecule Innovation
Discover how chemistry, AI-driven drug discovery, and evolving pharmaceutical economics are shaping the next generation of biopharmaceutical innovation.